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E-proteins define a distinct class of basic helix-
loop-helix transcription factors that are central 
regulators of cellular differentiation in various 
cell types and are essential for the development 
of B and T lymphocytes (Kee, 2009). There 
are three known E-protein coding genes in 
mammals, namely E2A (also called TCF3), E2-2 
(also called TCF4) and HEB (HeLa E-box 
binding protein; also called TCF12), which all 
bind to a DNA sequence motif called E-box 
(CANNTG). The E2A gene, which is located 
on chromosome 19p13.3, encodes for two dif-
ferent basic helix-loop-helix transcription fac-
tors, E12 and E47, which are generated by 
alternative splicing (Mellentin et al., 1989; 
Murre et al., 1989). E2A proteins form homo-
dimers and heterodimers with other HLH 
proteins to conduct their tissue- or cell type–
specific functions (Kee, 2009).
Alterations of E2A expression and activity 
have been suggested to support malignant trans-
formation of lymphoid cells. In mice, deletion 
of E2A, as well as enforced expression of its 
inhibitors, e.g., the inhibitor of DNA binding 
(Id) proteins, lead to rapid development of 
aggressive T cell lymphomas and T cell hyper-
proliferations (Bain et al., 1997; Yan et al., 
1997; Morrow et al., 1999). In humans, di-
minished E2A activity has been proposed as a 
pathogenetic mechanism in TAL1/SCL- or 
E2A-PBX1–induced leukemias (Park et al., 
1999; Aspland et al., 2001; O’Neil et al., 2004), 
and functional blockade of E2A is involved in 
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The transcription factor E2A is essential for lymphocyte development. In this study, we 
describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome 
(SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell 
cycle progression via derepression of the protooncogene MYC and the cell cycle regulator 
CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration 
of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic 
signaling pathways, including the Ras pathway. Several of these genes are down-regulated 
or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of 
E2A in human lymphoid cells and could help to develop new treatment strategies for 
human lymphomas with altered E2A activity.
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activity by immunoblotting and electrophoretic mobility shift 
assay. In both analyses, we reached levels comparable to en-
dogenous ones in other T cell leukemia–derived cell lines 
(Fig. S3 C). To substantiate our finding of reduced prolifera-
tion after E2A reconstitution, we measured DNA synthesis 
(determined by BrdU incorporation) and the respective cell 
cycle phases (determined by 7-aminoactinomycin D [7-AAD] 
staining) in parallel by a two-color flow cytometric analysis 
(Fig. 2 B). This experimental approach revealed that reexpres-
sion of E2A in Se-Ax cells significantly increased the fraction of 
cells in the G0/G1 phase at the expense of cells in the S phase 
of the cell cycle, suggesting that the reduced proliferation 
of Se-Ax cells after E2A reconstitution is caused by a G0/G1 
cell cycle arrest.
To establish a mechanistic link between E2A reduction 
and deregulated cell cycle control, we analyzed mRNA ex-
pression of the protooncogene MYC and the cell cycle regu-
lator CDK6 in Se-Ax cells. After E2A reconstitution, we 
observed significantly reduced mRNA levels of both genes 
(Fig. 2 C), suggesting a pathogenetically relevant link in these 
human T cell–derived lymphoma cells. In line with these in 
vitro data, we observed robust protein expression of CDK6 
in 7 out of 7 and, in accordance with previously published 
data (Vermeer et al., 2008), of MYC in 5 out of 6 primary SS 
tumor samples (Fig. 2 D). The high level of MYC expression 
in the SS tumor cells is in the majority of our SS cases most 
likely supported by genomic gains of chromosome 8q, which 
also includes the MYC locus (Fig. S1 and Table S4). Notably, 
the MYC-induced apoptotic program (Eischen et al., 1999) 
might be counteracted by the loss of 17p, including the tumor 
suppressor gene TP53, as demonstrated in a large number of 
our SS patient samples (Table S4).
To further investigate the impact of diminished E2A ex-
pression on SS tumor cells, we characterized E2A-dependent 
transcriptional changes in Se-Ax cells by microarray gene 
expression analyses. A highly overlapping, limited number 
of genes were responsive to E2A reconstitution with 
either E47 or E47-FD (Fig. S3 D and Table S5). Overall, 
far more genes were induced than repressed. Arguing for 
the biological relevance of our microarray analyses, the 
E2A-regulated genes in our data showed a significant over-
lap with E2A-dependent genes identified in E2A-deficient 
murine T cell lymphoma (Schwartz et al., 2006) and in a 
murine E2A-deficient hematopoietic progenitor cell line 
(Ikawa et al., 2006; Fig. S3 E and Table S6). In our dataset, 
among the E2A-induced genes were proapoptotic genes 
like BCL2L11 and BIK, genes known to modulate T cell–
specific signaling pathways and differentiation (DTX1, 
MAL), as well as negative regulators of oncogenic signaling 
pathways including the Ras signaling pathway (RASSF4, 
DAB2IP, RASA4, RGS16). The E2A-dependent up-regulation 
of these genes was confirmed by quantitative PCR (Fig. 3 A). 
In view of their dependency on E2A, expression would 
be expected to be down-regulated or lost in SS tumor 
cells because of their reduced E2A expression. Accordingly, 
BCL2L11 and MAL were previously described to be specifically 
the pathogenesis of human lymphomas (Mathas et al., 2006, 
2009; Lietz et al., 2007). However, a frequent genomic loss 
of E2A has not been identified in human lymphoid malig-
nancies so far. Arguing for a function as tumor suppressor in 
human cells, our study now demonstrates a recurrent dele-
tion of E2A in leukemic cells of patients suffering from Sézary 
syndrome (SS), an aggressive variant of primary cutaneous 
T cell lymphoma characterized by the presence of neoplastic 
T cells in skin, lymph nodes, and peripheral blood (Willemze 
et al., 2005).
RESULTS AND DISCUSSION
In a genome-wide analysis of peripheral blood mononuclear 
cells from 20 SS patients (Table S1) by array comparative 
genomic hybridization (array CGH), we identified a mini-
mal common region of chromosomal loss on chromosome 
19p13.3 in 70% (14/20) of patients (Fig. 1 A, Table I, Fig. S1, 
and Table S2).  This region of 1.4 Mb ranging from 
chr19:1368087 to chr19:2824434 (HG18) included the E2A 
gene locus. Fluorescence in situ hybridization (FISH) analy-
sis on highly enriched tumor cells using an E2A-specific 
probe confirmed a heterozygous loss of E2A in 8/12 ana-
lyzed SS patient samples (Fig. 1 B and Table I; for details on 
tumor cell enrichment see Materials and methods, Fig. S2, 
and Table S3). The number of cases with E2A deletion might 
even be underestimated because in two cases without dele-
tion in array CGH analysis, a deletion of E2A was detected 
by FISH (Table I). Concomitant with the genomic loss of 
E2A, the E2A mRNA expression level in enriched leuke-
mic cells of SS patients was significantly reduced compared 
with purified CD4+ T cells from healthy volunteers (Fig. 1 C 
and Fig. S3 A; note, that the Ct of E12/E47 or E47, re-
spectively, is significantly lower in CD4+ controls compared 
with SS patient samples. Hence, relative to GAPDH, SS 
patient samples express less E12/E47 or E47 mRNA, 
respectively, than the control CD4+ T lymphocytes), and 
immunohistochemistry showed weak or absent E2A protein 
expression in skin-infiltrating tumor cells in 15/15 patient 
samples (Fig. 1 D).
Among cutaneous T cell lymphomas, SS is unique in re-
spect to the presence of a high load of lymphoma cells in the 
peripheral blood. Because E2A interferes with cell cycle con-
trol (Park et al., 1999; Murre, 2005), we first investigated the 
impact of reduced E2A expression on the growth of malignant 
SS cells. To this end, we chose the SS-derived Se-Ax cell line, 
which is associated with a heterozygous loss of E2A (Fig. 1 B 
and Table I) and is characterized by reduced E2A mRNA and 
protein levels and impaired E-box DNA binding activity (Fig. 1, 
E and F and Fig. S3 B). After transient transfection with a 
Myc-tagged E47 construct and, alternatively, a construct cod-
ing for two covalently linked E47 molecules (E47-forced dimer, 
E47-FD), Se-Ax cells showed a pronounced reduction of 
proliferation (Fig. 2 A). No significant effect on apoptosis in-
duction was observed (unpublished data). To prove the bio-
logical significance of our transfection approach, we investigated 
transgene expression as well as the resulting E2A-DNA binding 
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samples, whereas reduced levels of RGS16 were observed 
in 2/4 SS samples compared with normal CD4+ T cells 
(Fig. 3, B and C).
down-regulated in SS cells (Kari et al., 2003; van Doorn 
et al., 2004). In our samples, BCL2L11, DTX1, and RASSF4 
were found to be down-regulated in 4/4 of our SS patient 
Figure 1. Loss of E2A is a common feature in SS tumor cells. (A) Array CGH results for chromosome 19 in tumor cells of 14 SS patients. The 
frequency of chromosomal gains and losses in percent of studied cases is shown to the right and to the left of the chromosome idiogram, respec-
tively. The genomic interval ranging from chr19: 200000–8599999 (HG18) is enlarged in the adjacent heatmap to the left. The coloring of each box 
in this heatmap represents the average array CGH ratio based on a 100-kb window for those 14 cases harboring E2A deletions according to CGH 
results. Chromosomal deletions and gains are shown in red and green, respectively (maximal color saturation at a log2 ratio of 0.6/0.6). The  
arrow indicates the genomic position of E2A. (B) Dual-color FISH analyses of purified tumor cells (patients #9 and #4) and the SS-derived cell line 
Se-Ax. Cells were hybridized with an E2A probe (red) and a control probe on 19qter (green). Pictures show representative examples of tumor cells 
without E2A deletion (Pat. #9: two red signals/two green signals) and cells with heterozygous deletion of the gene locus (Pat. #4, one red/two 
green; Se-Ax cells, two red/three green signals). Bars, 5 µm. (C) Quantification of E2A mRNA levels by real-time PCR in CD4+ T lymphocytes from 
healthy volunteers and purified leukemic SS cells from various patients, as indicated. (left) E2A mRNA expression in the various samples was ana-
lyzed relative to GAPDH by quantitative real-time PCR using primers recognizing both E2A splice variants, E12 and E47. (right) Box plot presenta-
tion of the comparison of Ct values of E2A in CD4+ controls (six male [CD4 #m] and six female [CD4 #f] samples) and SS patient samples (Pat. #). 
Results are shown for one of two independent experiments performed. (D) Immunohistochemistry of SS skin biopsies. Shown is double staining of 
the T cell marker CD3 (brown) and E12/E47 (purple). Dashed circle designates accumulations of malignant lymphocytes in the epidermis, so called 
Pautrier’s microabscesses. Arrows point to individual tumor cells with cerebriform nuclei. Bars, 50 µm. (E and F) E2A expression and DNA binding 
activity in various cell lines. (E, top) RT-PCR analysis of E2A mRNA expression in T cell–derived control cell lines Molt-14, Jurkat, and KE-37, as well 
as SS-derived Se-Ax cells. (bottom) Analysis of E2A protein expression in nuclear extracts of various cell lines by Western blotting (WB) using anti-
bodies to both E2A splice variants E12 and E47 (E12/E47) or to E47. GAPDH and PARP were analyzed as controls. Results are shown for one of 
three independent experiments performed. (F) EMSA of E2A DNA-binding activity in the various cell lines, as indicated. Sp1 DNA binding was ana-
lyzed as a control. Positions of the specific protein–DNA complexes are indicated. n.s., nonspecific complex. Results are shown for one of three 
independent experiments performed.
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likely by loss of transcriptional repression. Speculations 
on the interconnection of MYC, E2A, and TP53 and 
their synergistic influence on lymphoma development are 
substantiated by the high number of cases with simultane-
ous DNA copy number changes affecting these genes in 
our SS samples, as well as in E2A-deficient lymphoma cells 
in mice, a fact that most likely reflects the selective advan-
tage provided by the combination of these aberrations (Fig. S1 
and Table S4; Bain et al., 1997). Up-regulation of CDK6 as 
a consequence of reduced E2A levels could represent an-
other strategy of SS cells to provide a growth and survival 
advantage. Higher levels of CDK6 in SS cells might co-
operate with an aberrant activation of the NOTCH signal-
ing pathway, because CDK6 is necessary to exert the 
proliferative and anti-apoptotic function of NOTCH (Hu 
et al., 2009). NOTCH itself promotes T lymphomagenesis 
(Koch and Radtke, 2007) and is required for the survival of 
E2A-deficient lymphoma cells in mice (Reschly et al., 2006). 
In line with this concept, NOTCH activation has been re-
ported in SS cells (Kamstrup et al., 2010). In addition, our data 
show that E2A controls negative regulators of the oncogenic 
Apart from their central role in B and T lymphocyte 
development, E2A proteins have been suggested to act as 
tumor suppressors (Bain et al., 1997; Yan et al., 1997). Al-
though other genes located at 19p13.3 might also contrib-
ute to the pathogenesis of SS, our data identify the loss of 
E2A as a pathogenetically important defect of SS tumor 
cells and strongly support a role of E2A as a tumor suppres-
sor in human lymphoid cells. Mechanistically, we provide 
evidence that E2A controls a whole set of genes known to 
promote tumorigenesis. Concomitant with an increased 
proliferation rate, most likely caused by an impaired G0/G1 
cell cycle checkpoint, loss of E2A resulted in an up-regulation 
of MYC and CDK6. Both genes have been described as 
E2A target genes in lymphomas that emerge in E2A-
 deficient mice (Schwartz et al., 2006) and are known to be 
involved in lymphocyte proliferation, survival, and differ-
entiation (Herold et al., 2009; Hu et al., 2009). Further-
more, aggressive T cell lymphomas in E2A-deficient mice 
are characterized by high-level myc expression (Bain et al., 
1997). This suggests that up-regulation of the MYC onco-
gene is a common phenomenon after loss of E2A, most 
Table I. Loss of E2A in SS tumor cells
Patient no. Loss of E2A Purity of enriched tumor 
cellsArray CGH analysis FISH analysis (number of cells with deletion/number  
of analyzed cells)
%
1 yesc yes (149/200)e 96.7
2 yesc n.d –
3 yesc yes (198/200)e 99.1
4a yesc yes (167/200)e 93.2
5 yese yes (90/200)e 97.9
6 yesd n.d. –
7a yesc no (14/200)e 99.2f
8 yese n.d. –
9 noc no (3/200)e 97.4
10 noc no (4/200)e 96.9
11a yese no (12/200)d n.d.
12 noc n.d. –
13 yesc yes (126/200)e 98.4f
14 noc n.d. –
15a nob,c yes (106/200)d n.d.
16a noe yes (loss 28/200, gain 46/200)e 97.2
17 yese yes (50/200)e 98.4
18 yesc n.d. –
19 yese n.d. –
20 yese n.d. –
Se-Ax cell line yes yes (190/200)
 n.d.: not determined
aCGH and FISH analyses were performed with samples from different time points (see Table S1).
bhypotriploid cells, gain of chromosome 19 except 19p13.2-13.3. 
cAnalysis of PBMC cells.
dAnalysis of CD4-sorted cells.
eAnalysis of V-sorted cells. 
fPurity was determined with CD4 antibody only.
 o
n
 August 3, 2011
jem.rupress.org
D
ow
nloaded from
 
Published July 25, 2011
JEM Vol. 208, No. 8 1589
Br ief Definit ive Repor t
E2A dosage might facilitate the posttranslational degrada-
tion of E2A by NOTCH1 (Nie et al., 2003), which is aber-
rantly activated in SS cells (Kamstrup et al., 2010). Such a 
model, i.e., that lowering of wild-type E2A expression con-
tributes to human lymphomagenesis, is supported by the 
finding of aberrant up-regulation of E2A antagonists like 
inhibitory HLH proteins (O’Neil et al., 2004; Lietz et al., 
2007; Mathas et al., 2006, 2009) or the disruption of one 
E2A allele and maintenance of one wild-type allele as a re-
sult of translocations involving the E2A locus (Aspland et al., 
2001) in human lymphoma cells. That even a subtle dosage 
reduction of a putative tumor suppressor is sufficient for 
tumor formation has recently been formally shown for, e.g., 
PTEN (Alimonti et al., 2010).
Together, our data highlight the genomic loss of 19p13.3 
including the E2A locus as a pathogenetically important de-
fect of human T cell–derived SS lymphoma cells. Our results 
provide insights into how E2A acts as a tumor suppressor in 
human lymphoid cells and might help to develop new treat-
ment strategies for human lymphomas with lost or reduced 
E2A activity.
Ras signaling pathway (RASSF4, RASA4, and DAB2IP). 
Although altered expression of each of these genes alone 
might result in Ras activation (Eckfeld et al., 2004; Lockyer 
et al., 2001; Min et al., 2010), activation of the Ras signaling 
pathway has still to be proven formally in SS cells. There-
fore, the therapeutic potential of Ras inhibition in lympho-
mas with reduced E2A activity has to be investigated in 
future studies.
By FISH analysis, no homozygous deletion of E2A was 
observed. Direct sequencing of the coding regions of all 
E2A exons in leukemic SS cells from 13 patients did not re-
veal deleterious mutations or deletions (Table S7). Further-
more, the investigated E2A promoter regions in enriched 
SS cells compared with normal CD4+ T cells did not show 
altered methylation patterns Fig. S4. These data suggest on the 
one hand that the reduction of E2A expression after mono-
allelic E2A deletion might be sufficient for lymphoma pro-
gression, and on the other hand that selective pressure exists 
to retain one E2A copy to ensure a certain level of E protein 
activity, which is probably necessary for cellular survival at 
some time point during lymphomagenesis. Lowering the 
Figure 2. E2A-dependent proliferation 
and expression of MYC and CDK6 in SS 
cells. (A) Reconstitution of E2A expression in 
SS-derived Se-Ax cells. Se-Ax cells were 
transfected with Mock plasmid (control) or 
plasmids encoding Myc-tagged E47 (E47) or 
E47-FD, as indicated, along with pEGFP. 
EGFP+ cells were purified 48 h after transfec-
tion, pulsed with 1 µCi [3H]thymidine per well 
for another 20 h, and then [3H]thymidine 
incorporation was determined. Error bars 
denote standard deviation. Results are shown 
for one of three independent experiments 
performed. *, P < 0.001. (B) Proliferation and 
cell cycle analyses of Se-Ax cells after E2A 
reconstitution. Se-Ax cells were transfected 
as described in A. 48 h after transfection, 
cells were pulsed for 30 min with BrdU. 
Thereafter, transfected cells were gated based 
on their EGFP expression, and BrdU incorpo-
ration and 7-AAD staining was measured by 
flow cytometry in GFP+ cells. Left, represen-
tative examples for detection of BrdU incor-
poration and 7-AAD staining by flow 
cytometry in Mock- (top) or E47- (bottom) 
transfected Se-Ax cells. Positions and per-
centages of cells in cell cycle phases G0/G1, 
S, and G2/M are indicated. Right, summary  
of cell cycle analyses of Mock- vs. E47-FD– (top) 
and E47- (bottom) transfected Se-Ax cells. 
The fraction of cells in the respective cell 
cycle phases is indicated in percent. Error 
bars denote standard deviations. Results are shown for one of three independent experiments performed. *, P < 0.05; **, P < 0.005; NS, not significant. 
(C) Se-Ax cells were transfected with E47-FD and purified as described in A. Expression of MYC and CDK6 mRNA was assessed by quantitative PCR. 
Error bars denote 95% confidence intervals. Results are shown for one of three independent experiments performed. *, P < 0.001. (D) Representative 
MYC and CDK6 immunohistochemistry of each two SS skin biopsies. MYC and CDK6 stainings are in brown. Dashed circles designate Pautrier’s micro-
abscesses. CDK6, right, CDK6 expression in cells with frequent cerebriform nuclei within a dermal infiltrate from a patient with SS. Bars, 50 µm.
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Flow cytometric analysis of tumor cell samples. PBMCs and enriched 
tumor cells were analyzed on a FACSCalibur flow cytometer (BD) using 
CellQuest Pro software (BD) and WinMDI version 2.9 (The Scripps Research 
Institute). Antibodies directed against CD3, CD4, and CD8 were purchased 
from BD. All Vchain specific antibodies were from Beckman Coulter 
(see Table S3 for details).
Cell lines, culture conditions, proliferation, and cell cycle analysis. 
The human SS-derived cell line Se-Ax (Kaltoft et al., 1987); the T cell acute 
lymphoblastic leukemia (T-ALL) cell lines Molt-14, Jurkat, and KE-37; and 
H9 cells were cultured as previously described (Mathas et al., 2009), apart from 
adding 100 U/ml recombinant human IL-2 (Sigma-Aldrich) to Se-Ax cell cul-
ture medium. Se-Ax cells were electroporated in OPTIMEM I (Invitrogen) 
using a Gene-Pulser II (Bio-Rad Laboratories) with 500 F and 0.24 kV. Trans-
fection efficiency was determined by pEGFP-N3 (Takara Bio Inc.) co-
 transfection and subsequent flow cytometry. Cells were transfected with 30 µg 
myc-tagged E47 or E47-FD expression constructs (Sigvardsson et al., 1997; Lietz 
et al., 2007) or 30 µg control plasmid pcDNA3.1 (Invitrogen), along with 10 µg 
of pEGFP-N3. 48–72 h after transfection, EGFP+ cells were enriched by FACS 
sorting, and sorted cells were used for proliferation assays as well as RNA and 
protein preparation. Proliferation of cells was determined by measurement of 
DNA synthesis after [3H]thymidine incorporation using standard protocols. 
Parallel measurement of BrdU incorporation for determination of proliferation 
and of 7-AAD staining for determination of cell cycle position was performed by 
use of the APC BrdU Flow kit (BD). In brief, 48 h after transfection, cells were 
pulsed for 30 min with BrdU, and BrdU incorporation and 7-AAD staining in 
gated EGFP+ cells was determined by flow cytometry.
Array CGH. Initial array CGH analysis was done by means of a submegabase 
resolution BAC array, as described previously (Erdogan et al., 2006). DNA copy 
number changes were defined by circular binary segmentation (Olshen et al., 
2004) in combination with a log2 threshold of 0.2/0.2. Aberrations encom-
passing chromosome arm 19p were further verified and fine-mapped by hybrid-
izations onto a 400k whole genome (Agilent; Gene Expression Omnibus [GEO] 
accession no. GPL9777) and a customized 60k chromosome 19p oligonucle-
otide array (Agilent; GEO accession no. GPL10304), respectively, following the 
manufacturer’s recommendations (Table S8). The customized array com-
prised 52,828 oligonucleotides evenly covering chromosomal region chr19: 
1–28,500,000 (NCBI36; HG18). Array CGH data discussed in this work are 
available (Barrett and Edgar, 2006) under GEO accession no. GSE19000.
MATERIALS AND METHODS
Patient samples. 20 clinically well-characterized patients with SS were in-
cluded in our study. Diagnoses were established according to the World Health 
Organization-European Organization for Research and Treatment of Cancer 
classification for cutaneous lymphomas (Willemze et al., 2005). Detailed clinical 
information on all patients and blood samples are summarized in Table S1. The 
use of human material was approved by the Local Ethics Committee of 
the Charité-Universitätsmedizin Berlin and performed in accordance with the 
Declaration of Helsinki.
Clonality analysis and sequencing of tumor cell–specific TCR 
rearrangements. PBMC samples were analyzed for the presence of a 
clonally expanded tumor cell population by TCR-rearrangement PCR 
analysis using primers and protocols developed within the BIOMED-2 
BMH4-CT98-3936 Concerted Action initiative (van Dongen et al., 2003). 
Only samples that showed almost single clonal product peaks in the fluo-
rescent fragment analysis (FFA) were directly used for subsequent CGH 
analysis. To identify the V chain expressed by the respective tumor cells, 
amplification products were purified and complete TCR rearrangements 
were sequenced using the BigDye Terminator V1.1 cycle sequencing kit 
(Applied Biosystems) and subsequent analysis by high resolution electro-
phoresis on an ABI PRISM 310 Genetic Analyzer. Identification of 
the involved V, D, and J segments was done by submitting the received 
TCR sequence to the International Immunogenetics Information System 
V-QUEST tool (http://imgt.cines.fr/IMGT_vquest/share/textes/; Brochet 
et al., 2008; Lefranc et al., 2009). Results for each patient are presented 
in Table S3.
Enrichment of primary SS tumor cells from PBMCs. PBMCs were 
isolated from whole blood or leukapheresis samples by density gradient 
centrifugation using Ficoll-Paque-Plus (GE Healthcare). For enrichment 
of tumor cells, PBMCs were incubated for 30 min with the respective 
fluorochrome-conjugated V antibody (Beckman Coulter; see Table S3 for 
details) at a concentration of 5–20 µl/106 cells in 100 µl of MACS buffer, 
followed by incubation with anti-fluorochrome MicroBeads (Miltenyi 
Biotec). Cells were magnetically separated by use of LS columns (Miltenyi 
Biotec) according to the manufacturer’s recommendations. Where indi-
cated, tumor cells were enriched after incubation with anti-CD4 microbeads 
(Miltenyi Biotec). The purity of enriched cells was determined by 
flow cytometry.
Figure 3. E2A-regulated genes in SS tumor 
cells. (A) Se-Ax cells were transfected with 
Mock plasmids (control) or plasmids encoding 
E47-FD, along with pEGFP. 48 h after transfec-
tion, EGFP+ cells were enriched. Expression of 
various genes, as indicated, was assessed by 
quantitative PCR. Error bars denote 95%  
confidence intervals. Results are shown for  
one of four independent experiments per-
formed. *, P < 0.5; **, P < 0.01; ***, P < 0.001.  
(B and C) mRNA expression of various genes in 
purified CD4+ T cells from healthy donors (CD4 
#1 to CD4 #4) compared with enriched tumor 
cells derived from four SS patients (Pat. #2, #3, 
#4, #5; numbers refer to the same patients 
listed in Table I). If mRNA expression was de-
tectable in SS samples by semiquantitative PCR 
(B), mRNA expression was quantified by real-
time PCR in the respective samples (C). Error 
bars denote 95% confidence intervals. Results 
are shown for one of two independent experi-
ments performed.
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and as 5-CCTACCTCCCTTTGCAGGCT-3; Exon 7, s 5-GCA-
GGGGTTGTTCTCATGGC-3 and as 5-AAGCTTCGCCAGGA-
CACAGG-3; Exon 8, s 5-GAAACGGGGTGGTAGATGTG-3 and as 
5-GAGGGGAGCTGGTAAGGTG-3; Exon 9, s 5-CTATCCC-
GCCCCCTTCTAC-3 and as 5-GTTCACCTCTGCTCCATGC-3; 
Exon 10, s 5-GCACGAGCGTATGGTAGGAC-3 and as 5-CTCT-
CAGGGCCAGCAGAC-3; Exon 11+12, s 5-CTGTGCAGGACG-
GCAGAAC-3 and as 5-CCGCAAAGCCTTCACAGA-3; Exon 13, s 
5-ATCAGGCCATGCTCACACCC-3 and as 5-TCTGTCCTG-
CAAATTCTGTCGG-3; Exon 14, s 5-CATGCGGAAGGGACATGA-3 
and as 5-GGTGGCTGCCTCCAACCT-3; Exon 15, s 5-GCTGGCCT-
CAGGTTTCAC-3 and as 5-ACCCTGACCCCCACCACTA-3; Exon 
16a, s 5-CCAAGACCTGGTTTTTCCAG-3 and as 5-GAGGGAGA-
CAGTGAGGTTGG-3; Exon 16b, s 5-ACCCACACTGGGAGGCCGT-3 
and as 5-CAGTCATGGCAATGCGGTCA-3; Exon 17, s 5-TACC-
CTCTCCACAACCCAGC-3 and as 5-AGCATCTGCACCTGGG-
TGTG-3; Exon 18, s 5-ACATCTTTCTCCTCCCTGGG-3 and as 
5-GTGTGGATGTGGATGAAGCC-3.
Bisulfite pyrosequencing. Bisulfite pyrosequencing of two amplicons 
located in the E2A promoter region was performed according to Lamprecht 
et al., 2010 with few modifications. In brief, genomic DNA was bisulfite 
converted using the EpiTect Bisulfite Conversion kit (QIAGEN). In a post-
PCR amplification, locus-specific primers were used with one primer bio-
tinylated at the 5 end (PCR and sequencing primer sequences and analyzed 
region are shown in the following paragraph). For E2A amplification reac-
tions, PyroMark PCR kit (QIAGEN) was used according to standard proto-
cols. After initial denaturation (95°C for 15 min), PCR consisted of 45 
cycles of 94°C for 30 s, annealing temperature for 30 s, and 72°C for 30 s, 
followed by a final synthesis at 72°C for 10 min. Pyrosequencing was per-
formed using the Pyrosequencer ID and the DNA methylation analysis soft-
ware Pyro Q-CpG 1.0.9 (Biotage), which was also used to evaluate the ratio 
T:C (mC:C) at the CpG sites analyzed. All assays were optimized and vali-
dated using commercially available completely methylated DNA (Millipore) 
and pooled DNA isolated from peripheral blood of 10 healthy male and fe-
male controls, respectively.
Primer sequences and conditions used for bisulfite-pyrosequencing 
were as follows: E2A_promA, s 5-TTAGTTTATGGAGGGTAGGTA-3 
(5 modification, biotin) and as 5-AAACCCCAACAATATTCA-3 
(annealing temperature, 55°C; amplicon length, 126 bp; analyzed region 
[ucsc, HG18], chr19:1,601,941-1,602,066); E2A_promA_seq, 5-CCCTA-
AATTACTTTACTAT-3; E2A_promB, s 5-TAAGGGGGAAATTG-
AGGT-3 and as 5-CCCTAATACTAAACCCTACATACAA-3 (5 mod-
ification, biotin; annealing temperature, 55°C; amplicon length, 139 bp; 
analyzed region [ucsc, HG18], chr19:1,596,870-1,597,008); E2A_promB_seq, 
5-ATTGAGGTTTTGGAG-3.
Electrophoretic mobility shift assay (EMSA) and immunoblotting. 
Preparation of whole-cell and nuclear extracts, as well as EMSA, was performed 
as previously described (Mathas et al., 2006). The following double-stranded 
oligonucleotides were used for EMSA: E2A (E5) sense  5-AGCTCCAGAA-
CACCTGCAGCAG-3 and E2A (E5) antisense, 5-AGCTCTGCTGCA-
GGTGTTCTGG-3; Sp1 sense, 5-AGCTATTCGATCGGGGCGGGGCG-
AGC-3 and Sp1 antisense, 5-AGCTGCTCGCCCCGCCCCGATC-
GAAT-3. After annealing, oligonucleotides were end-labeled with [-32P]dCTP 
using Klenow fragment. Positions of protein–DNA complexes were visualized 
by autoradiography. For supershift analyses, mouse monoclonal antibody to 
E12/E47 (clone G98-271; BD) was used. For immunoblot analyses, the follow-
ing primary antibodies were used: mouse monoclonal antibody to E12/E47 
(clone G98-271; BD), mouse monoclonal antibody to E47 (clone G127-32; BD), 
goat polyclonal antibody to PARP-1 (sc-1561; Santa Cruz Biotechnology, Inc.), 
and mouse monoclonal antibody to -actin (A5316; Sigma-Aldrich). Filters 
were incubated with horseradish peroxidase–conjugated secondary antibodies. 
Bands were visualized with the enhanced chemiluminescence system 
(GE Healthcare).
FISH analysis of E2A. FISH analysis was performed on enriched tumor 
cells using the specific DNA-probes spanning the E2A gene (RP11-690N6) 
and control probes for 19qter (D19S989; Kreatech) to judge the copy num-
ber of chromosome 19. Hybridization, detection, dual color image acquisi-
tion, and image analysis were performed as previously described (Schröck 
and Padilla-Nash, 2000).
RNA preparation, semiquantitative, and real-time PCR analy-
ses. Total RNA was prepared using the RNeasy kit (QIAGEN). First 
strand cDNA-synthesis was performed by use of the first-strand cDNA 
synthesis kit (AMV; Roche) adding oligo-p(dT)15 primer according to 
the manufacturer’s recommendation. For semiquantitative PCR analyses 
primers were as follows: GAPDH, sense (s) 5-ATGCTGGCGCTGA-
GTAC-3 and antisense (as) 5-TGAGTCCTTCCACGATAC-3; E2A, s 
5-CACCCTCCCTGACCTGTCT-3 and as 5-GGAGCTGAAAGCAC-
CATCTG-3; RGS16, s 5-TGGAGAGAGTCGTTCGACCTG-3 and 
as 5-TGTCCTCTTGCACTTGCTTTGC-3; RASSF4, s 5-GGTG-
GGGATGACTTTCAATG-3 and as 5-GTGGCTTCCAAGCTAT-
GCTC-3; BCL2L11 s 5-GGGTGACTGGAGAGCTCATT-3 and as 
5-AAAGCACAGGAAGTTGCACA-3; DTX1, s 5-CTGGTCACAG-
CATCAGGCTA-3 and as 5-GGTCTTGTGGTGGATCTCGT-3. 
Real-time PCR analyses were performed using Power SYBR Green Master-
mix and the ABI StepOnePlus real-time PCR system (Applied Biosystems). 
Three technical replicates were performed for each reaction and specificity 
of PCR products was confirmed by melting curve analysis and subsequent 
agarose gel electrophoresis. Relative expression values were determined 
using the 2-Ct method. Calculations were done with the StepOnePlus soft-
ware, taking into account the determined primer efficiency of each primer 
set used. Primers used for real-time PCR analyses were as follows: myc, s 
5-TCAAGAGGTGCCACGTCTCC-3 and as 5-TCTTGGCAGCAG-
GATAGTCCTT-3; CDK6, s 5-GGCTGTGTGAACCAGCCCAAG-3 
and as 5-TGGCCAGGCCTAGACAGGCA-3; DTX1, s 5-TCAG-
GCTACGAGGGCGTGCT-3 and as 5-CCACGAGGCACAGCAG-
GTGG-3; BIK, s 5-AGCTCCTGGAACCCCCGACC-3 and as 
5-CGCAGGGCCAATGCGTCACT-3; MAL, s 5-GGTGGGAAGTGGC-
GACCGTG-3 and as 5-ACAAGATGGGGCGCTCGGGA-3; RASSF4, 
s 5-TTGGGCGTGGAAGTCCCCCA-3 and as 5-AGGCGCTGCAG-
CATCGTCAG-3; BCL2L11, s 5-TGCCAGCCCTGGCCCTTTTG-3 
and as 5-GGCCTGGCAAGGAGGACTTGG-3; RGS16, s 5-TCAGCC-
GCCTCTGCCACTCT-3 and as 5-CGGCTGGCTTCCTCACT-
GCC-3; RASA4, s 5-TTTGGCGGCTCGCACGTCAT-3 and as 
5-CACCTTCCGCAGCGCAGACA-3; DAB2IP, s 5-CTGTGTG-
CAGCCCTCGAGCC-3 and as 5-GAGGTGCTCGTTGTCCCCGC-3; 
TBP, s 5-CAGGAGCCAAGAGTGAAGAACA-3 and as 5-AGCTG-
GAAAACCCAACTTCTGT-3; GAPDH, s 5-CTCTGCTCCTCCT-
GTTCGAC-3 and as 5-TTAAAAGCAGCCCTGGTGAC-3; TaqMan 
Gene Expression Assays Hs01012686_m1 (E47), Hs0102692_g1 (E12/E47), 
and Hs03929097_g1 (GAPDH). For statistical analyses, independent Student’s 
t tests were used. All PCR products were verified by sequencing.
Direct sequencing of E2A coding regions. All 18 coding exons of E2A 
(E12 and E47) were amplified from 10–20 ng of genomic DNA isolated 
from enriched tumor cells using AccuPrime GC-Rich Polymerase (Invitro-
gen) according to the manufacturer’s recommendations. PCR products were 
directly sequenced by using the BigDye Terminator V1.1 cycle sequencing 
kit (Applied Biosystems) and subsequent analysis on an ABI PRISM 310 
Genetic Analyzer. Primer sequences for amplification and sequencing were as 
follows: Exon 1, s 5-CCTCCCTGTTTCTCCCTGTC-3 and as 5-GAA-
AACCTTCCCGTGAACTG-3; Exon 2, s 5-TGTAGGGTTTGGTT-
TGCCAC-3 and as 5-CACTGTCTTCAACAGACCCTTG-3; Exon 3, 
s 5-AGGTTTGCCCCTGAGATGAT-3 and 3 as 5-CAGGACTCA-
AACCCATGTCC-3; Exon 4, s 5-GGACATGGGTTTGAGT-
CCTG-3 and as 5-GTGAACGCTGGGGACTTG-3; Exon 5, s 
5-CCCTCAGGATGTTCCTTGGG-3 and as 5-GAGAGGGTGGGT-
GACAGATTTG-3; Exon 6, s 5-AACAGCCTGGGGTCTGGATG-3 
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 Figure S1.  DNA copy number changes detected in tumor cells of 20 patients with SS. The frequency of chromosomal gains and losses in per-
centage of studied cases is shown to the right and to the left, respectively. 
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 Figure S2.  Tumor cell enrichment by magnetic cell sorting. PBMCs of patient 16 were analyzed before (top) and after (bottom) enrichment of tu-
mor cells by magnetic sorting of V  6-6 + cells for CGH analysis. (left) Flow cytometric analysis of cells after staining with APC-labeled anti-CD4 and FITC-
labeled anti–V  6-6 antibodies. The percentage of CD4 + V  6-6 + cells is indicated. (right) Clonality analysis of T cells. Shown are the fl uorescent fragment 
analysis profi les of “reaction 3” of the TCR  -rearrangement PCR showing a dominant clonal peak (for details on clonality analysis refer to Materials and 
methods). The dominant (blue) peak is identical in the unsorted and the enriched V  6-6 + cell sample, demonstrating that these cells represent the clon-
ally expanded tumor cell population. Green peaks indicate amplifi cation of rearrangements involving J  1 gene segments; blue peaks indicate amplifi ca-
tion of rearrangements involving J  2 segments. 
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 Figure S3.  Expression of E47 mRNA in SS patient samples; E2A EMSA and protein expression analysis after E2A reconstitution of Se Ax 
cells; and gene expression analysis after E2A reconstitution. (A) Quantifi cation of  E2A mRNA levels by real-time PCR in CD4 + T lymphocytes from 
healthy volunteers and purifi ed leukemic SS cells from various patients, as indicated. Left,  E2A mRNA expression in various samples was analyzed relative 
to  GAPDH by quantitative real-time RT-PCR using primers recognizing the  E2A splice variant  E47 . Right, box plot presentation of the comparison of   Ct 
values of  E2A in CD4 + controls and SS patient samples. Results are shown for one of two independent experiments performed. (B) Specifi city control of 
DNA bound complexes by supershift analysis. EMSA of nuclear extracts of Molt-14 and KE-37 cells without preincubation (-) or with preincubation with 
antibody to E2A (E12/E47). Data show EMSA of E2A-containing complexes with the   E5 element as probe. Positions of E2A complexes and complexes 
supershifted (ss) with antibody to E2A are indicated. n.s., nonspecifi c complexes. (C) Se-Ax cells were transfected with Mock plasmid (control) or plasmids 
encoding myc-tagged E47 (E47) or E47-FD, as indicated, along with pEGFP. 48 h after transfection, EGFP + cells were enriched and protein extracts were 
prepared. Left, E47 and E47-FD protein expression in purifi ed transfected cells was analyzed by immunoblotting, H9 and KE-37 cells were analyzed as 
controls. Right, E2A DNA binding activity in purifi ed Se-Ax cells and Molt-14 and KE-37 control cell lines was analyzed by EMSA as described in  Fig. 1 F . 
Results are shown for one of four independent experiments performed. (D) Se-Ax cells were transfected and purifi ed as described in C. mRNA was ex-
tracted and gene expression profi ling was performed using Agilent Whole Genome 4 × 44K arrays. Background corrected and normalized intensity values 
were then used for gene-wise linear model fi tting using LIMMA, P values were adjusted for multiple testing using the method from Benjamini and Hoch-
berg. The number of signifi cantly deregulated genes (adjusted P value ≤ 0.05) with a log 2 -fold change of ≤1 or ≥ -1 and the according overlap of the 
comparisons Mock vs. E47-FD and Mock vs. E47 are shown as Venn diagram. Results were obtained from two independent experiments. (E) To compare 
the entire spectrum of E2A-regulated genes in our microarray analyses of Se-Ax cells after E47 reconstitution with those regulated in murine lymphoid 
cells, we compared our data with the datasets of Schwartz et al. (2006; GEO accession no.  GSE4784 ) and Ikawa et al. (2006; GEO accession no.  GSE4693 ). 
These microarray datasets were generated with murine  E2A -defi cient T cell lymphoma cells and murine  E2A -defi cient hematopoietic progenitor cells, 
respectively. For all datasets, genes were deemed signifi cantly regulated, when they showed a fold change in expression of at least > 1.5 or < 0.5. The 
mouse-identifi ers for the features of both  GSE4784 and  GSE4693 were mapped to human homologues for subsequent analysis of the overlap of regu-
lated genes. The Venn diagram depicted shows the overlap of all genes that were up-regulated at least 1.5-fold in either dataset (of the 7 genes in our 
dataset, that were down-regulated at least 0.5-fold, none was found to be down-regulated to at least this degree in any of the other two datasets). This 
diagram shows that the overlap of our dataset with either of the other datasets is signifi cant as calculated by hypergeometric test. 
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 Figure S4.  Methylation of two regions within the promoter region of  E2A in SS patient samples compared with purifi ed CD4 + T lympho-
cytes from healthy volunteers. Three CpGs of the  E2A promoter region A ( E2A _promA) and region B ( E2A _promB) were analyzed by bisulfi te pyrose-
quencing, respectively. For each sample, the DNA methylation is shown in percentage for each individual CpG site. Methyl. Control, in vitro methylated 
DNA; pool pb, pooled DNA isolated from PBMCs. 
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 Table S1. Detailed patient information 
Patient 
no.
Sex Identical 
TCR-R in 
blood and 
skin*
Time point 
of blood 
sample 
(MM/YY)
Age in 
years
Peripheral blood parameters Treatment before 
time point of blood 
sample
 WBC 
 count/nl 
 % 
 atypical 
cells 
(Sézary 
cells) 
 % CD4 + /CD3 +  CD4 + /CD8 + 
ratio 
 % V  + /CD4 + 
1 F + 03/99 76 6.4 0 92 21 89 UVB, Pr
2 F + 12/02 67 20.9 80 99 99 n.d. Ch+P, IFN
3 F n.d. 08/99 95 20.9 64 >99 49 >99 -
4 M + 01/05a 73 22.2 60 >99 665 99 UV, ECP
02/05 73 22.7 76 96 712 n.d. UV, ECP
5 F n.d. 02/00 58 28.7 59 >99 94 98 -
6 M + 10/09 59 31.1 33 99 136 n.d. IFN, ECP
7 M + 01/07a 59 12.6 31 >99 63 97 IFN+ECP, Bex+SAHA, 
Ch+Pr
03/07 59 23.0 33 99 321 n.d. IFN+ECP, Bex+SAHA, 
Ch+Pr,   CD52
8 M + 10/09 89 7.5 0 91 n.d. 74 PUVA
9 M + 08/02 67 17.2 26 91 98 81 CyA, PUVA, IFN, ECP
10 M + 02/03 74 13.2 25 97 29 93 PUVA, IFN
11 F n.d. 08/00 86 6.9 21 97 24 96 PUVA Cyc+Pr, 
Cyc+Pr+V, Ch+Pr
11/00a 86 4.5 n.d. 94 n.d. n.d. PUVA Cyc+Pr, 
Cyc+Pr+V, Ch+Pr
12 M n.d. 04/02 52 8.0 16 >99 n.d. n.d. PUVA, ECP, IFN, Dx, 
MTX
13 F + 08/02 79 17.2 28 94 49 68 PUVA, Ch+Pr
14 F n.d. 08/99 65 21.3 72 99 90 n.d. ECP
15 F + 08/07a 64 21.3 n.d. 95 n.d. n.d. IFN, ECP, Ch+P, PUVA, 
MTX, Cyc, Bex+SAHA
03/08 64 30.1 28 n.d. n.d. n.d. IFN, ECP, Ch+P, PUVA, 
MTX, Cyc, Bex+SAHA
16 F + 08/08 79 9.2 8 92 20 84 ECP, IFN
01/09a 79 7.6 n.d. 91 15 n.d. ECP, IFN
17 F + 09/08 72 8.1 25 99 197 94 ECP, PUVA, IFN
18 M + 03/97 62 43.0 44 n.d. n.d. n.d. PUVA
19 M + 01/10 49 11.9 n.d. 97 48 96 -
20 F + 03/10 62 11.8 n.d. 96 31.9 89 ECP
TCR-R, T cell receptor rearrangement; WBC, white blood cell; Ac, acitretin; Bex, bexarotene; Ch, chlorambucil; CyA, cyclosporin A; Cyc, cyclophosphamide, Dx, doxorubicin; ECP, 
extracorporeal photopheresis; Flu, fl udarabine; MTX, methotrexate; Pr, prednisone; PUVA, psolaren + irradiation with long wave ultraviolet light; SAHA, suberoylanilide 
hydroxamic acid; UV, irradiation with ultraviolet light (wave length not specifi ed); UVB, irradiation with short wave ultraviolet light; V, vincristine;   CD52, Alemtuzumab 
(humanized monoclonal antibody targeting the CD52 antigen); n.d., not determined; *, as determined by TCR-rearrangement PCR and subsequent fl uorescent fragment 
analysis.
aSamples used for FISH analyses
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 Table S2. Chromosomal positions of 19p deletions including 
 E2A 
Patient no. 19p deletion
start (bp) end (bp)
1 19pter 5634354
2 19pter 8313679
3 1368087 4038576
4 19pter 4312210
5 329606 19692685
6 19pter 1881426
7 19pter 3413889
8 902763 4116979
9 – –
10 – –
11 265457 4110578
12 – –
13 794978 4424528
14 – –
15 – –
16 – –
17 19pter 5763726
18 19pter 2824434
19 19pter 4033360
20 19pter 7992388
Chromosomal positions (HG18) are based on circular binary segmentation and a 
log 2 threshold of   0.2.
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 Table S3. Sequence analysis of the clonal TCR  -rearrangements obtained from patients with SS 
Patient 
no.
3  V  -region N1 D  N2 5  J  -region V  D  J  Pr Ab clone
1  TGTGCCAGTAGT.....  CTCC  .GGACAGGG...  AG  CTCCTATAATTCACCCCTCCACTTT 19 1 1-6 + E17.5F3.15.13
2  TGTGCCAGCTCACCAC.  .....TAGCGGGAGGG  C  ......CCGGGGAGCTGTTTTTT 18 2 2-2 + BA62.6*
3  TGTGCCAGCAGT.....  C  .GGACTAGC.......  CTACTATAT  .................TTTT 2 2 2-3 - n.a.
 TGTGCCAGTAG......  CACC  GGGACTA.........  CTAT  ....CACCGGGGAGCTGTTTTTT 19 2 2-2 + E17.5F3.15.13
4  TGTGCCAGCAGT.....  CCAACTTT  .........TTCACCCCTCCACTTT 6-5 – 1-6 + IMMU 222
5  TGTGCCAGTAGT.....  GG  .....AGGG...  CTGGGG  ........GAAAAACTGTTTTTT 19 1 1-4 + E17.5F3.15.13
6  TGTGCCAGTAGTATA..  AGA  GGGA........  GTCT  CTCTGGAAACACCATATATTTT 19 1 1-3 + E17.5F3.15.13
7  TGTGCCAGCAGCC....  CTCGT  ....CTAGCGGGAG..  AGAT  .........CATTCAGTACTTC 3-1 2 2-4 + FIN9
8  TGTGCCAGC........  GTCG
CCTCC 
 GGGAC.......  CCATAACTCTG  .........GCCCCAGCATTTT 2 1 1-5 - n.a.
 TGCAGTGCTAG.  AG  .....AGGGGGC  TC  ....CAGATACGCAGTATTTT 20 1 2-3 + MPB2D5
9  TGTGCCAGCAGCC....  CCCA  .GGACAGGG...  CG  .....TATGGCTACACCTTC 3-1 1 1-2 + FIN9
10  TGTGCCAGCAGTGA...  GGTTA  ..GACTAGCGG.....  T  ...CTACAATGAGCAGTTCTTC 2 2 2-1 + IMMU 546
11  TGCGCCAGC.......  CGC  ..GACAG.....  CTCCTACGAGCAGTACTTC 5-1 1 2-7 + IMMU 157
12  TGTGCCAGCAGCTTGG  .GGACAGG....  CCT  CTCTGGAAACACCATATATTTT 5-4 1 1-3 + ~
13  TGTGCCAGCAGCTTGG  CAAG  ....CACTGAAGCTTTCTTT 5-6 - 1-1 + 36213
14  TGTGCCAGCAGCTTAG.  GTCCAGGAG  .......GCGGGG...  AGA  ..............CTGTTTTTT 7-9 2 2-2 - n.a.
15  TGTGCCAGCAGCTTGG  CCACCC  ....CTAG........  ......CAATGAGCAGTTCTTC 5-4 2 2-1 + ~
16  TGTGCCAGCAGTTAC..  CC  ....CAG.....  CTCCTACAATGAGCAGTTCTTC 6-6 1 2-1 + JU74.3
17  TGTGCCAGCAGTTTAG.  GG  ....CAGGG...  ....CACTGAAGCTTTCTTT 12-3 1 1-1 + 56C5.2
18 Sequence analysis not done.
19  TGCAGTGCTAG...  TTT  GGGACTAGCGGGG...  .......AATGAGCAGTTCTTC 20 2 2-1 + MPB2D5
20  TGTGCCAGCAGTTTATC  GGGC
GCGGCT 
 ..GACAG.....  AC  .....ATAATTCACCCCTCCACTTT 27 1 1-6 + CAS1.1.3
The representative clone-specifi c sequence of the junctional region is shown. The nomenclature of the corresponding V, D, and J germline segments is based on the 
international ImMunoGeneTics information system. Pr, Productive gene rearrangement; ~, no specifi c antibody available. *, no specifi c binding of the antibody within the CD3/
CD4 double-positive cell fraction; n.a., not applicable (unproductive TCR  -rearrangement).
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 Table S4. Chromosomal gains and losses of  TP53 and  MYC 
Patient no. Array CGH analysis FISH analysis
(number of cells with deletion/number of analyzed cells)
Loss of Gain of Loss of
 TP53  MYC  TP53 
1 yes no yes (195/200)
2 yes yes n. n.d
3 yes no yes (199/200)
4 b yes yes yes (200/200)
5 a yes yes yes (195/200)
6 a yes no n.d.
7 b yes yes no (0/200)
8 a yes yes n.d.
9 yes yes yes (100/200)
10 yes no yes (200/200)
11 a , b yes yes yes (196/200)
12 no yes n.d.
13 no yes no (1/200)
14 yes no n.d.
15 b no yes yes (loss 37/200, gain 48/200)
16 a , b yes no yes (178/200)
17 a yes yes yes (193/200)
18 yes yes n.d.
19 a yes yes n.d.
20 a no no n.d.
Se-Ax yes yes yes (100/100)
n.d., not determined.
 a CGH was performed on enriched tumor cells
 b CGH and FISH analyses were performed with samples from different time points (see Table S1).  o
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 Table S5. E2A-regulated genes in Se-Ax cells 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_23_P74012 9.36 10.15 1.00E-06 0.00 SPRR1A
A_23_P93348 7.15 7.19 0.00 0.00 LTB
A_23_P104555 5.62 6.82 3.00E-06 0.00 ANKRD2
A_23_P200579 5.61 4.63 0.00 0.00 ELA3B
A_23_P428129 4.95 6.28 3.00E-06 0.00 CDKN1C
A_23_P34700 4.67 4.08 6.20E-05 4.50E-05 TNNT2
A_23_P112481 4.54 4.71 0.00 0.00 AQP3
A_32_P94444 4.5 2.01 0.00 0.04 PRSS2
A_23_P111766 4.4 1.95 0.00 0.04 A_23_P111766
A_24_P927304 4.38 3.79 5.60E-05 4.10E-05 TNNT2
A_23_P148737 4.28 5.18 0.01 0.00 MYBPH
A_23_P218047 4.18 4.92 3.30E-05 4.00E-06 KRT5
A_23_P27133 4.15 6.66 0.01 0.00 KRT15
A_23_P95213 4.05 5.1 0.00 9.00E-06 SFTPC
A_23_P132175 4.05 6.57 1.90E-05 0.00 RTN4R
A_23_P112482 3.95 4.06 0.00 0.00 AQP3
A_23_P106024 3.91 6.47 0.00 0.00 JAG2
A_23_P48088 3.9 4.06 1.90E-05 5.00E-06 CD27
A_23_P64051 3.9 6.19 2.00E-05 0.00 CDC42BPG
A_23_P1912 3.86 2.27 0.00 0.01 ZP1
A_32_P16315 3.68 2.85 0.00 0.00 ENST00000272035
A_23_P96158 3.55 5.01 0.02 0.00 KRT17
A_32_P103669 3.54 5.14 0.00 0.00 GOLGA8E
A_24_P257022 3.53 3.02 0.00 0.00 TNNT2
A_23_P115261 3.53 2.45 0.00 0.01 AGT
A_24_P610945 3.39 4.97 0.02 0.00 ENST00000311208
A_23_P17134 3.32 3.18 8.30E-05 3.50E-05 MAL
A_32_P59302 3.3 3.6 0.00 8.70E-05 HIVEP3
A_23_P140884 3.27 2.74 0.01 0.01 BC014971
A_23_P102113 3.2 2.58 3.00E-06 3.00E-06 WNT10A
A_32_P73507 3.15 2.85 1.00E-06 0.00 THC2647902
A_23_P332960 3.12 4.37 3.30E-05 1.00E-06 TMEM80
A_24_P177236 3.1 5.03 0.00 7.40E-05 CABP7
A_23_P250102 3.09 1.76 1.50E-05 0.00 CAND2
A_24_P887857 3.09 4.55 0.04 0.00 LOC650517
A_24_P62469 3.08 5.27 9.30E-05 1.00E-06 PLCH2
A_23_P39955 3.04 2.26 0.00 0.00 ACTG2
A_23_P363769 3.01 3.65 0.01 0.00 KRT86
A_24_P265346 2.95 4.56 0.04 0.00 KRT14
A_23_P500010 2.92 3.71 0.02 0.00 KLK12
A_23_P5845 2.91 3.52 3.00E-06 0.00 KHK
A_23_P372834 2.88 2.5 0.00 0.00 AQP1
A_23_P102117 2.88 2.27 1.30E-05 1.50E-05 WNT10A
A_23_P210482 2.88 2.76 1.00E-06 0.00 ADA
A_23_P421306 2.86 3.2 2.00E-06 0.00 SYT12
A_23_P163492 2.85 5.56 0.00 8.00E-06 BAIAP3
A_23_P304897 2.8 5.39 0.00 2.20E-05 BDKRB2
A_23_P210176 2.78 1.58 0.00 0.01 ITGA6
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S5. E2A-regulated genes in Se-Ax cells (Continued) 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_24_P8371 2.76 3.76 0.00 0.00 LOC124976
A_23_P69293 2.76 2.55 1.00E-06 1.00E-06 CHDH
A_23_P207345 2.76 3.52 6.00E-05 5.00E-06 ADAM11
A_23_P39925 2.71 3.86 0.00 5.00E-06 DYSF
A_24_P589028 2.7 4.08 0.01 0.00 AK026750
A_23_P348208 2.61 3.5 0.00 0.00 SPRR1A
A_23_P111860 2.6 4.75 0.00 6.00E-06 FLJ10324
A_23_P37702 2.54 5.24 0.00 6.00E-06 TPSAB1
A_23_P107401 2.51 1.41 0.00 0.00 TIMP2
A_23_P16252 2.5 3.28 0.00 7.70E-05 KLK1
A_23_P129695 2.49 2.96 0.04 0.01 VASN
A_23_P142878 2.49 2.31 0.00 0.00 ATOH8
A_23_P21495 2.46 5.15 3.30E-05 0.00 FCGBP
A_32_P38093 2.39 2.82 0.00 6.90E-05 THC2632909
A_23_P39931 2.36 3.39 3.50E-05 1.00E-06 DYSF
A_23_P64661 2.36 2.56 0.00 4.40E-05 ARHGAP9
A_24_P382579 2.35 2.89 0.01 0.00 OXT
A_23_P146554 2.35 2.91 0.00 0.00 PTGDS
A_23_P159237 2.35 3.93 0.02 0.00 GPR20
A_23_P41390 2.34 3.56 8.30E-05 2.00E-06 SH3TC1
A_23_P44335 2.31 2.69 1.20E-05 1.00E-06 ENTPD8
A_23_P22143 2.25 5.79 0.00 5.00E-06 PDE6B
A_23_P319583 2.25 3.00 0.00 4.40E-05 RIMS3
A_23_P163682 2.24 3.67 0.01 0.00 RHBDF1
A_23_P101392 2.22 3.09 0.00 3.10E-05 TMEM38A
A_24_P329795 2.22 2.28 0.04 0.01 C10orf10
A_23_P413641 2.2 2.78 9.70E-05 7.00E-06 PREX1
A_23_P112798 2.19 5.21 3.00E-06 0.00 CRIP2
A_23_P24104 2.19 2.05 0.01 0.00 PLAU
A_23_P33196 2.19 1.68 0.00 0.00 COL5A2
A_23_P112774 2.16 4.58 0.00 3.00E-06 PTP4A3
A_23_P161769 2.16 4.22 0.00 3.00E-06 FXYD2
A_23_P53257 2.14 3.18 0.01 0.00 AVIL
A_24_P295590 2.13 2.22 3.00E-06 1.00E-06 RASSF4
A_24_P357847 2.12 1.49 8.00E-06 1.80E-05 BC030813
A_23_P33511 2.09 4.29 0.01 3.50E-05 AX721087
A_32_P48825 2.08 2.27 0.01 0.00 KRT72
A_32_P39440 2.07 1.53 2.00E-06 3.00E-06 BC030813
A_24_P31165 2.07 1.78 0.00 0.00 GFAP
A_32_P159192 2.06 1.48 3.00E-06 6.00E-06 ENST00000295339
A_24_P142118 2.03 1.31 7.00E-06 3.00E-05 THBS1
A_24_P378019 2.02 3.48 0.03 0.00 IRF7
A_24_P364838 2.01 3.34 5.90E-05 1.00E-06 SLC9A3R2
A_32_P148118 2.00 1.51 1.90E-05 3.30E-05 ENST00000331696
A_23_P98786 1.99 3.93 0.03 0.00 MYO7A
A_32_P86763 1.99 3.54 0.00 1.70E-05 TGM2
A_23_P75260 1.98 2.08 5.90E-05 1.40E-05 RASSF4
A_23_P21382 1.95 5.56 0.00 0.00 LAMB2
A_32_P98072 1.95 2.17 0.04 0.01 ENST00000368804
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S5. E2A-regulated genes in Se-Ax cells (Continued) 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_24_P122921 1.93 2.28 8.00E-06 1.00E-06 BCL2L11
A_23_P206212 1.93 1.17 1.90E-05 0.00 THBS1
A_23_P357185 1.92 1.68 6.00E-06 4.00E-06 CHDH
A_24_P923251 1.91 3.18 0.01 0.00 TGM2
A_23_P147326 1.9 1.88 0.02 0.01 SERINC2
A_23_P360874 1.89 2.67 0.00 4.90E-05 DKFZp434K1815
A_24_P140608 1.88 1.58 0.00 0.00 HBEGF
A_23_P34804 1.88 1.53 3.50E-05 3.90E-05 NTRK1
A_23_P105562 1.86 3.54 0.00 2.10E-05 VWF
A_23_P258887 1.86 2.84 0.00 0.00 ALDH1L1
A_24_P303524 1.84 3.42 0.03 0.00 MICALL2
A_23_P138495 1.82 2.81 1.20E-05 0.00 PTPRE
A_24_P383609 1.82 2.61 0.00 0.00 NANOS1
A_23_P346093 1.81 2.52 0.00 4.10E-05 TMC8
A_23_P150547 1.8 0.81 0.00 0.02 PGA3
A_23_P217845 1.8 1.84 0.01 0.00 RGS16
A_23_P160800 1.8 1.25 0.02 0.04 NR0B2
A_24_P639701 1.8 1.25 1.30E-05 3.50E-05 AY062331
A_24_P943263 1.79 3.1 0.00 4.50E-05 RASA4
A_23_P61688 1.78 2.87 3.50E-05 1.00E-06 SLC12A7
A_24_P213494 1.78 3.08 0.00 3.60E-05 PTPRE
A_23_P320578 1.77 1.77 0.00 0.00 RGS16
A_23_P21800 1.75 1.21 6.50E-05 0.00 BC032451
A_24_P272146 1.75 1.31 3.00E-06 6.00E-06 IGKC
A_24_P32295 1.73 3.06 0.00 8.00E-06 C19orf36
A_24_P490109 1.73 1.34 2.70E-05 3.80E-05 A_24_P490109
A_23_P316612 1.73 4.44 0.00 6.00E-06 GLIS1
A_24_P265506 1.72 1.2 1.20E-05 2.90E-05 NTRK1
A_23_P429977 1.72 4.02 5.00E-06 0.00 KCNQ1
A_23_P17316 1.71 5.29 0.00 1.00E-06 C20orf58
A_23_P416581 1.71 4.69 0.00 0.00 GNAZ
A_23_P128230 1.69 2.99 0.02 0.00 NR4A1
A_23_P84596 1.69 1.53 0.00 0.00 MGC29506
A_23_P147822 1.69 2.46 0.01 0.00 EPS8L2
A_32_P46238 1.66 2.58 0.00 3.10E-05 LOC339240
A_24_P402510 1.66 2.91 0.02 0.00 SAMD11
A_24_P66578 1.65 1.21 0.00 0.00 ENST00000377221
A_24_P90349 1.65 2.55 0.01 0.00 TMEM80
A_23_P349966 1.65 2.16 0.01 0.00 TMEM130
A_24_P182461 1.64 1.55 0.02 0.01 IGSF3
A_23_P252306 1.63 1.06 0.00 0.00 ID1
A_23_P4962 1.61 2.82 0.00 1.70E-05 NLRP5
A_24_P924631 1.61 1.33 0.00 0.00 THC2500892
A_23_P413051 1.6 0.99 0.01 0.02 NOXO1
A_23_P360240 1.6 2.14 0.00 7.70E-05 MYEOV
A_23_P165778 1.59 1.18 0.02 0.03 MLPH
A_24_P823096 1.58 2.34 0.01 0.00 AL109708
A_24_P571824 1.58 2.85 0.01 0.00 A_24_P571824
A_23_P341860 1.56 3.53 0.00 1.00E-06 BC073815
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S5. E2A-regulated genes in Se-Ax cells (Continued) 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_24_P226008 1.56 1.94 0.00 0.00 MGLL
A_23_P126278 1.55 1.16 0.00 0.00 CHIT1
A_32_P42236 1.54 3.35 0.00 5.00E-06 BM461836
A_23_P61810 1.53 3.99 0.02 3.50E-05 BAIAP2
A_23_P371039 1.52 3.93 0.01 1.50E-05 NTSR1
A_23_P29282 1.51 2.24 0.00 7.00E-06 NPTXR
A_24_P196562 1.5 3.27 0.00 1.00E-06 FXYD2
A_23_P38630 1.5 0.96 0.01 0.03 SSTR2
A_23_P72330 1.5 1.13 0.00 0.00 A_23_P72330
A_24_P880000 1.49 1.22 1.50E-05 1.50E-05 AF088004
A_23_P319598 1.48 2.62 0.02 0.00 C4BPB
A_23_P159227 1.48 1.76 0.01 0.00 ADAM15
A_23_P143981 1.47 3.63 0.01 9.00E-06 FBLN2
A_23_P500741 1.47 4.65 0.00 1.00E-06 CBFA2T3
A_24_P35400 1.46 3.88 6.50E-05 0.00 SARDH
A_23_P35456 1.46 1.87 0.00 0.00 SH3PXD2A
A_23_P11787 1.46 4.16 0.00 0.00 WNT4
A_24_P331704 1.45 2.49 0.00 4.10E-05 KRT80
A_24_P395966 1.45 1.55 3.00E-05 6.00E-06 ZBP1
A_23_P50674 1.45 2.61 0.02 0.00 C19orf36
A_23_P35330 1.44 1.46 0.00 0.00 HIVEP3
A_23_P10559 1.44 2.65 0.00 1.00E-06 AATK
A_23_P66073 1.44 2.45 0.02 0.00 AF113013
A_23_P256158 1.43 2.95 0.00 2.00E-06 ADRA2C
A_23_P32500 1.43 4.1 0.00 3.00E-06 STAB1
A_23_P422851 1.42 1.37 0.00 0.00 CABLES1
A_23_P14769 1.42 0.66 0.00 0.01 FES
A_23_P170534 1.41 2.15 0.00 0.00 FUT7
A_23_P86599 1.41 3.58 0.01 1.80E-05 DMBT1
A_23_P500501 1.39 2.69 0.00 5.00E-06 FGFR3
A_23_P251855 1.38 2.56 0.00 6.00E-06 SLC12A7
A_24_P404245 1.37 2.61 0.01 7.60E-05 PCYT2
A_23_P10391 1.36 0.79 0.00 0.00 COL5A2
A_23_P147331 1.36 1.3 0.00 0.00 SERINC2
A_24_P206305 1.35 2.95 0.02 8.80E-05 MICALL2
A_23_P356004 1.35 2.42 1.90E-05 0.00 KCNIP3
A_23_P73023 1.34 1.19 0.00 0.00 TBC1D1
A_24_P687305 1.33 1.79 0.02 0.00 DKFZp434K191
A_24_P123601 1.33 2.19 0.01 0.00 DDR1
A_23_P51187 1.32 3.01 0.05 0.00 PRKCZ
A_23_P128993 1.32 1.06 5.90E-05 6.90E-05 GZMH
A_23_P93311 1.31 2.2 0.00 7.80E-05 DDR1
A_24_P188116 1.31 2.19 0.01 0.00 ANKRD2
A_23_P101193 1.3 1.19 0.00 0.00 MYO5B
A_23_P76749 1.28 0.73 0.01 0.03 GALNTL1
A_24_P623768 1.28 0.79 0.01 0.03 AF131813
A_24_P290751 1.28 1.74 0.00 0.00 DTX1
A_24_P48898 1.27 1.37 0.04 0.01 APOL2
A_24_P346431 1.27 2.7 0.04 0.00 TNS3
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S5. E2A-regulated genes in Se-Ax cells (Continued) 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_32_P35947 1.27 4.31 0.00 1.00E-06 LOC651758
A_23_P259141 1.27 1.28 5.90E-05 1.80E-05 ZBP1
A_23_P22723 1.26 1.14 0.04 0.02 ATP2B3
A_23_P47614 1.26 2.48 0.01 0.00 PHLDA2
A_23_P68786 1.26 2.92 0.01 3.20E-05 PRODH
A_24_P693986 1.26 1.54 0.01 0.00 LOC388610
A_24_P406132 1.26 1.39 0.02 0.01 MAPK13
A_32_P17182 1.25 0.67 0.00 0.01 N48043
A_24_P50890 1.25 3.39 2.00E-04 0.00 PVRL1
A_23_P168449 1.24 2.58 0.05 0.00 RASA4
A_23_P14508 1.23 1.24 0.00 0.00 TTC9
A_23_P137381 1.22 1.37 0.04 0.01 ID3
A_23_P49546 1.22 2.93 0.00 1.00E-06 GRIN2C
A_23_P417415 1.22 1.02 0.00 0.00 ACOT11
A_23_P42882 1.21 4.26 0.00 0.00 CAMK2B
A_23_P52286 1.21 1.19 0.00 0.00 RP11-529I10.4
A_24_P213503 1.2 2.2 0.00 5.00E-06 PTPRE
A_23_P161659 1.19 1.29 0.00 4.20E-05 SYT13
A_23_P165333 1.18 1.15 0.00 0.00 BIN1
A_23_P258088 1.17 0.79 0.00 0.00 PACSIN1
A_23_P53081 1.17 2.27 0.02 0.00 OSBPL5
A_23_P168388 1.16 1.25 0.01 0.00 GIMAP8
A_23_P95029 1.16 0.66 0.00 0.01 SNTB1
A_23_P354175 1.16 1.58 0.01 0.00 TMEM129
A_23_P213944 1.16 0.93 0.00 0.00 HBEGF
A_24_P677559 1.16 0.75 0.00 0.00 BC032451
A_23_P93641 1.15 1.71 0.02 0.00 AKR1B10
A_23_P54846 1.15 1.04 0.02 0.01 HERPUD1
A_23_P76538 1.14 1.9 0.00 6.30E-05 TESC
A_23_P431933 1.14 1.56 0.01 0.00 CAMKK1
A_23_P127781 1.13 1.68 0.01 0.00 SCGB1D1
A_23_P311912 1.13 3.7 0.01 4.00E-06 C14orf78
A_23_P145376 1.13 1.19 0.04 0.01 MAPK13
A_32_P149011 1.12 0.58 0.00 0.04 CN479126
A_23_P390984 1.12 2.38 0.02 0.00 KCNH6
A_23_P169137 1.12 1.48 0.00 6.60E-05 NINJ1
A_23_P502314 1.12 1.27 0.02 0.00 CD97
A_32_P5976 1.11 2.14 0.02 0.00 NUDT14
A_24_P91094 1.11 2.24 0.00 7.00E-06 RPIP8
A_23_P60990 1.11 3.69 0.00 1.00E-06 FLJ22671
A_24_P372913 1.11 1.63 0.00 1.50E-05 TCF1
A_23_P110569 1.1 1.43 0.03 0.00 TRIM36
A_23_P502312 1.1 1.16 0.01 0.00 CD97
A_24_P129341 1.1 1.64 0.00 0.00 AKR1B10
A_23_P123848 1.1 2.08 0.00 1.30E-05 DAB2IP
A_32_P201292 1.09 0.92 0.00 0.00 BU587941
A_24_P132383 1.09 1.25 0.00 0.00 GIMAP8
A_32_P9543 1.09 1.94 0.05 0.00 APOBEC3A
A_24_P83758 1.09 2.49 0.00 6.00E-06 ENST00000292728
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S5. E2A-regulated genes in Se-Ax cells (Continued) 
Agilent probe ID Log 2 -fold change:
E47-FD vs. Mock
Log 2 -fold change:
E47 vs. Mock
Adjusted p-value:
E47-FD vs. Mock
Adjusted p-value:
E47 vs. Mock
Gene symbol
A_24_P367289 1.08 1.8 0.01 0.00 DDR1
A_23_P76901 1.08 1.36 0.00 0.00 PLEKHG3
A_24_P156993 1.08 1.05 0.01 0.00 BIN1
A_23_P19894 1.07 0.91 0.01 0.01 AQP1
A_24_P152845 1.07 1.59 0.00 2.50E-05 LOC340888
A_23_P6746 1.07 1.99 0.01 4.80E-05 IQSEC1
A_23_P79978 1.05 0.84 0.05 0.04 SLC24A3
A_24_P145629 1.05 0.99 0.03 0.02 SERINC2
A_23_P67198 1.05 1.47 0.00 1.40E-05 CPAMD8
A_23_P157247 1.04 2.00 0.00 6.00E-06 MGC9712
A_23_P404667 1.04 2.36 0.03 0.00 BIK
A_23_P12463 1.04 0.79 0.00 0.00 QSCN6
A_23_P209799 1.03 1.58 0.00 0.00 MYO7B
A_23_P34537 1.03 1.62 0.02 0.00 EPHX1
A_23_P165840 1.03 1.32 0.01 0.00 ODC1
A_23_P214408 1.02 2.81 0.00 0.00 UNC93A
A_23_P395460 1.02 3.38 0.01 3.00E-06 KIF1A
A_23_P165927 1.02 3.72 0.01 1.00E-06 STMN3
A_24_P103434 1.01 2.92 0.00 0.00 UNC93A
A_23_P401076 1.01 1.64 0.04 0.00 SUSD3
A_23_P35092 -1.09 -1.13 0.02 0.01 IL19
Se-Ax cells were transfected as described in Fig. S3. Table of all genes that showed at least a log 2 -fold change > 1.0 or < -1.0 and an adjusted p-
value of P < 0.05 in the comparison E47-FD  vs . Mock. According log 2 -fold changes and adjusted p-values of the comparison E47  vs . Mock are also 
stated. Calculation of adjusted p-values was done as described in Fig. S3.
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 Table S6. Genes overlapping between our dataset and GSE4784, GSE4693, or GSE4784 and GSE4693 
Overlap between our data and Schwartz et al. 
(GSE4784) 
Overlap between our data and Ikawa et al. 
(GSE4693) 
Overlap between our data and Schwartz et al. 
and Ikawa et al. 
ALDH1L1 ADA ATOH8
AMPD3 ADRA2C BTG2
ATF3 AKR1B10 CAMK2B
ATOH8 ART3 CBFA2T3
AZI1 ATOH8 CDKN1A
BCL2L11 BIK CHIT1
BDKRB2 BMF CPNE5
BTG2 BTG2 DYSF
BZRAP1 CAMK2B EDN2
C3orf54 CBFA2T3 GADD45B
CAMK2B CCDC96 GPR56
CBFA2T3 CD82 HERPUD1
CCNL1 CDKN1A HES1
CDKN1A CHIT1 HTRA3
CDKN1C CPNE5 ID2
CHIT1 CTSA IGHM
CPEB4 CUZD1 KCNQ1
CPNE5 DTX1 PDGFA
CSRP1 DYSF PTGDS
DLL1 EDN2 PTP4A3
DYSF ENTPD8 SSTR2
EDN2 FES SYNGR2
EPB41L4B FGFR3 TCIRG1
FBLN2 GADD45B XBP1
FGF9 GNAZ ZDHHC8
GADD45B GPR20
GLCCI1 GPR56
GLDC HERPUD1
GPR56 HES1
GRHL1 HTRA3
GRIN2C ID2
HERPUD1 ID3
HES1 IER5L
HIVEP3 IFIH1
HTRA3 IGHM
ID1 IRF7
ID2 KCNQ1
IGHM KLK1
IGSF3 KLK10
IL11RA LFNG
IL21R LSP1
ITGA6 LTB
JAG2 MAL
KCNJ12 MAP1LC3B
KCNQ1 MARCO
KLHL21 MGLL
KRT17 MYO7A
KRT5 NINJ1
MAN2A1 NINJ2
NOXO1 OXT
NUAK2 PDGFA
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 Table S6. Genes overlapping between our dataset and GSE4784, GSE4693, or GSE4784 and GSE4693 (Continued) 
Overlap between our data and Schwartz et al. 
(GSE4784) 
Overlap between our data and Ikawa et al. 
(GSE4693) 
Overlap between our data and Schwartz et al. 
and Ikawa et al. 
NUDT14 PHLDA2
PDGFA PKD1
PRODH PRAP1
PRSS3 PRKCZ
PTGDS PTGDS
PTP4A3 PTP4A3
PTPRE RASSF4
PVRL1 RGR
RASA4 RSAD2
RASAL1 SERINC2
RBM38 SGCA
RGS16 SLC24A3
SEMA3F SLCO4A1
SFTPC SNAI3
SLC24A6 SPRR1A
SPACA3 SPRR1B
SPRR3 SSTR2
SSTR2 STMN3
SYNGR2 SYNGR2
SYT12 TCIRG1
TCIRG1 TESC
TMEM129 TFPI
TPST2 TGFB3
XBP1 TGM2
ZDHHC8 TNFRSF25
ZNF238 TNNT2
TUBB3
WNT10A
WNT4
WNT5B
XBP1
ZBP1
ZDHHC8
ZG16
 Shown are all gene symbols, which in either dataset comparison are up-regulated at least 1.5-fold in the datasets used for the respective comparison. 
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 Table S7. Sequencing results of  E2A coding regions 
Patient no. SNPs and mutations detected in coding region Type Zygosity
4 rs1140828
rs1052692
rs1052696
rs8140
synonymous
non synonymous
synonymous
synonymous
heterozygous
heterozygous
heterozygous
heterozygous
5 none - -
6 none - -
7 rs1140828
rs1052692
rs1052696
rs8140
synonymous
non synonymous
synonymous
synonymous
homozygous
heterozygous
heterozygous
homozygous
10 rs1140828
rs1052692
rs1052696
rs8140
synonymous
non synonymous
synonymous
synonymous
heterozygous
heterozygous
heterozygous
heterozygous
11 rs1140828
rs8140
synonymous
synonymous
homozygous
homozygous
12 none - -
13 none - -
15 rs8140
rs2074888
synonymous
non synonymous
homozygous
homozygous
16 Mutation (G → A; 1572856)
rs1140828
rs8140
synonymous
synonymous
synonymous
heterozygous
heterozygous
heterozygous
17 rs1140828
rs8140
synonymous
synonymous
homozygous
homozygous
19 rs1140828
rs1052692
rs1052696
rs8140
synonymous
non synonymous
synonymous
synonymous
homozygous
heterozygous
heterozygous
homozygous
20 rs1140828
rs8140
synonymous
synonymous
homozygous
homozygous
Shown are all detected single nucleotide polymorphisms (SNPs) and yet undescribed alterations (mutations) within the coding regions of  E12 as well as  E47 in enriched tumor 
cells from SS patients. For the detected mutation the altered base and its position according to HG18 is given in brackets.
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 Table S8. Array platforms used in this study 
Patient no. Array platform
1 BAC 400k -
2 BAC -  60k 
3 BAC 400k -
4 BAC -  60k 
5 BAC 400k -
6 BAC  400k -
7 BAC -  60k 
8 BAC 400k -
9 BAC - -
10  BAC - -
11 BAC 400k -
12 BAC 400k -
13 BAC 400k -
14 BAC - -
15 - 400k -
16 BAC 400k -
17 BAC 400k -
18 BAC 400k -
19 BAC 400k
20 BAC 400k
Se-Ax BAC - -
Experiments in bold type were used for defi ning the genomic coordinates of DNA 
copy number changes visualized in Fig. 1 A, Fig. S1, and Table S2. BAC, 36k whole-
genome tiling path BAC array. 400k, 400k whole-genome oligonucleotide array. 60k, 
custom 60k chromosome 19p oligonucleotide array.
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